Vaccine 2011-10-19

CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle.

Jiling Ren, Liang Yang, Haifei Xu, Yongsheng Zhang, Min Wan, Guoying Liu, Lixia Zhao, Liying Wang, Yongli Yu

Index: Vaccine 29(45) , 7960-5, (2011)

Full Text: HTML

Abstract

Foot-and-mouth disease (FMD) is a highly contagious disease of cloven-hoofed animals. To prevent the spread of FMDV, inactivated virus vaccines are used to immunize animals in developing countries. However, there are safety concerns. In addition, it is difficult to distinguish the vaccinated animals from those naturally infected ones. In our lab, we have developed a recombinant FMDV vaccine named A7. A7 contained multiple B cell and T cell epitopes, which reside in a capsid protein (VP1) of FMDV. To enhance its immunogenicity, A7 was formulated with CpG ODN RW03 in combination with Montanide ISA 206 (ISA), and the resultant vaccine (A7+ISA+CpG ODN RW03) was used to immunize mice and cattle. It was found that CpG ODN RW03 and ISA combination could facilitate A7 to induce a vigorous and long-lasting specific antibody response in mice and cattle. After FMDV challenge, 80% (4/5) of the calves immunized with A7+ISA+CpG ODN RW03 were protected, which was superior to those immunized with A7+ISA (25%, 1/4) or inactivated FMDV vaccine (50%, 2/4). These findings suggest that CpG ODN RW03 could be used with Montanide ISA 206 as a potent adjuvant for recombinant FMDV in cattle.Copyright © 2011 Elsevier Ltd. All rights reserved.


Related Compounds

Related Articles:

Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.

2009-08-06

[Vaccine 27(36) , 5020-5, (2009)]

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

2010-03-02

[Vaccine 28(10) , 2236-42, (2010)]

Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei.

2010-01-01

[PLoS ONE 5(8) , e12294, (2010)]

Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.

2012-10-01

[Clin. Vaccine Immunol. 19(10) , 1633-40, (2012)]

Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.

2010-07-01

[J. Virol. Methods 167(1) , 10-6, (2010)]

More Articles...